Prof Karim Fizazi speaks to ecancer at ASCO 2024 about a study looking at health-related quality of life and pain with the use of lutetium-177–PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer .
He explains that patients were randomized 1:1 to open-label lutetium-177–PSMA-617 or ARPI change (abiraterone/enzalutamide).
Prof Fizazi reports that self-reported data collected from two questionnaires showed that lutetium-177–PSMA-617 improved time to deterioration in quality of life by approximately 40%.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
